COVID-19 Pandemic - The government presents its daily update
QUÉBEC CITY, March 25, 2022 /CNW Telbec/ - The most recent data on the evolution of COVID-19, in the last 24 hours, in Québec show:
2,203 new cases, bringing the total number of people infected to 953,498*;
12 new deaths, for a total of 14,300 deaths;
1,048 hospitalizations, for a decrease of 14 compared to the previous day;
93 new entries,
107 new discharges;
59 people in intensive care, for an increase of 2 compared to the previous day;
10 new entries,
8 new discharges;
16,150 samples conducted on March 23;
122,045 self-declared rapid tests so far, including 96,477 positive: 1,135 declared for yesterday, including 968 positive.
*Note that the number of cases listed is not representative of the situation since access to screening centres is restricted to priority clienteles.
Vaccination
8,011 doses administered are added, that is 8,064 doses in the last 24 hours and -53* doses before March 24, for a total of 18,592,149 doses administered in Québec. Outside Québec, a total of 312,508 doses were administered, for a cumulative total of 18,904,657 doses received by Quebecers.
*The decrease is due to corrections made to the database.
To follow the evolution of the data on a daily basis, consult the open data or the INSPQ website at https://www.donneesquebec.ca/recherche/fr/organization/msss or at https://www.inspq.qc.ca/covid-19/donnees. Note that certain data, especially the number of cases, deaths and doses administered, may be subject to daily readjustment for previous days, given that a catch-up is necessary due to a delay in data entry.
A reminder concerning public health instructions:
To limit the spread of the coronavirus as much as possible, it is important to follow basic preventive measures such as hand washing, physical distancing, wearing a face covering and following the instructions in effect.
Remember that in the event of symptoms, it is always essential to isolate yourself and consult one of the self-care guides or call 1-877-644-4545 (or the telephone code corresponding to the region concerned) to find out the measures to be taken.
Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural immunity among seniors aged 65 or older, is...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through...
HLS Therapeutics Inc. ("HLS" or the "Company") announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.
A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and...
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of...
Summary
Products: All lots of Accel-Ondansetron ODT (4 mg and 8 mg tablets); Mint-Betahistine (8 mg, 16 mg and 24 mg tablets); PMS-Pirfenidone (267 mg and 801 mg tablets)Issue: Health products ? Product safetyWhat to do: Return the affected products...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock...